Department of Pathology, Sapporo Medical University, School of Medicine, South-1 West-17, Chuo-Ku, Sapporo 060-8556, Japan.
Exp Mol Pathol. 2012 Feb;92(1):27-32. doi: 10.1016/j.yexmp.2011.09.016. Epub 2011 Oct 2.
The aim of this study was to establish a novel efficient cancer DNA vaccine approach. Many tumor-associated antigens (TAAs) have been reported; however, there is little information of the efficiency of each TAA. Normal cells barely undergo mitosis, whereas cancer cells divide frequently and grow well. Thus, G2/M-related antigens are cancer cell-specific and are regarded to be suitable candidates as targets of cancer immunotherapy. In this study, we compared the efficiencies of G2/M-related antigens including Birc5, Aurka, Nke2 and Plk1 by using a DNA vaccination model. Mice that had been immunized with G2/M-related antigens coding plasmid were challenged with CT26 colon cancer cells. Interestingly, Birc5- and Aurka-immunized mice showed an anti-tumor effect, whereas Nek2- and Plk1-immunized mice did not show any anti-tumor effect. We investigated the expression of G2/M-related antigens in cancer stem-like cell (CSC)/cancer-initiating cell (CIC) population to verify the difference in the anti-tumor effect. CSCs/CICs were isolated as side population (SP) cells using Hoechst 33342 dye from CT 26 cells. It was found that Birc5 and Aurka are expressed in both CSCs/CICs and non-CSCs/CICs (shared antigens), whereas Nek2 and Plk1 are expressed preferentially in non-CSCs/CICs (non-CSC antigens). Therefore, antigen expression in the CSC/CIC population might be related to the anti-tumor efficiency of cancer immunotherapy. Furthermore, we established a heat shock protein (Hsp90)-fused Birc5 plasmid to improve anti-cancer immunity. Birc5 fused to the N-terminal region of Hsp90 showed a stronger anti-tumor effect, whereas Birc5 fused to the C-terminal region of Hsp90 did not show enhancement compared with Birc5. These observations indicate that expression in the CSC/CIC population is essential to achieve tumor regression and that fusing antigens to the N-terminal region of Hsp90 enhances the anti-tumor effect.
本研究旨在建立一种新的有效癌症 DNA 疫苗方法。已经报道了许多肿瘤相关抗原(TAA);然而,每个 TAA 的效率信息却很少。正常细胞很少经历有丝分裂,而癌细胞分裂频繁且生长良好。因此,G2/M 相关抗原是癌细胞特异性的,被认为是癌症免疫治疗的合适靶标。在本研究中,我们使用 DNA 疫苗模型比较了包括 Birc5、Aurka、Nke2 和 Plk1 在内的 G2/M 相关抗原的效率。用 G2/M 相关抗原编码质粒免疫的小鼠用 CT26 结肠癌细胞进行攻击。有趣的是,Birc5 和 Aurka 免疫的小鼠显示出抗肿瘤作用,而 Nek2 和 Plk1 免疫的小鼠没有显示出任何抗肿瘤作用。我们研究了 G2/M 相关抗原在癌症干细胞样细胞(CSC)/癌症起始细胞(CIC)群体中的表达,以验证抗肿瘤效果的差异。CSC/CIC 作为侧群(SP)细胞从 CT26 细胞中用 Hoechst 33342 染料分离。发现 Birc5 和 Aurka 在 CSC/CIC 和非 CSC/CIC 中均有表达(共同抗原),而 Nek2 和 Plk1 则优先在非 CSC/CIC 中表达(非 CSC 抗原)。因此,CSC/CIC 群体中的抗原表达可能与癌症免疫治疗的抗肿瘤效率有关。此外,我们建立了一种热休克蛋白(Hsp90)融合 Birc5 质粒以提高抗癌免疫。Birc5 融合到 Hsp90 的 N 端区域显示出更强的抗肿瘤作用,而 Birc5 融合到 Hsp90 的 C 端区域与 Birc5 相比没有增强作用。这些观察结果表明,在 CSC/CIC 群体中的表达对于实现肿瘤消退是必要的,并且将抗原融合到 Hsp90 的 N 端区域可增强抗肿瘤作用。